{
  "docId": "019de071-f36b-702d-acba-b009d415a6aa",
  "docSlug": "7f10ea97b4031d406788e9f98a2cb8e4",
  "documentTitle": "Alkermes | Investor Conference Presentation Deck | 36 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 36,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f36b-702d-acba-b009d415a6aa/26",
  "deckHref": "/decks/019de071-f36b-702d-acba-b009d415a6aa",
  "deckJsonHref": "/decks/019de071-f36b-702d-acba-b009d415a6aa.json",
  "deckAnchorHref": "/decks/019de071-f36b-702d-acba-b009d415a6aa#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.07,
        "y": 0.23
      },
      "kind": "list",
      "text": "Design: Inherently active, stable fusion protein",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13712ee2-6ee3-40ac-85f6-418de7968edb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.07,
        "y": 0.8
      },
      "kind": "list",
      "text": "Strategy: Clinical strategy focused on difficult-to-treat cancers with clear unmet need; FDA Fast Track Designation granted in mucosal melanoma* and platinum-resistant ovarian cancer**",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2845ec0b-2676-43d6-a77b-e61a3538ccc9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.07,
        "y": 0.66
      },
      "kind": "list",
      "text": "Dosing Flexibility: Multiple potential routes of administration and dosing schedules being investigated in the clinic",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3eef980b-bf74-4f5d-a585-a80fb36cb955",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.07,
        "y": 0.37
      },
      "kind": "list",
      "text": "PD Profile: Dose-dependent expansion of NK and CD8+ T cells, with minimal effects on Tregs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fbf99ed-dc45-4d6e-84d4-a20955114953",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.07,
        "y": 0.51
      },
      "kind": "list",
      "text": "Clinical Benefit: Anti-tumor activity observed both as a single agent and with checkpoint inhibitors (CPI); Anti-tumor activity observed in CPI-unapproved tumor types and post-CPI settings",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dae17116-55f5-406f-b48d-55fe18b012b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.15,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "* Also granted FDA Orphan Drug Designation; **In combination with pembrolizumab. Treg: Regulatory T cell; NK cell: Natural killer cell",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a145136-d5bb-4e7f-aa7e-94478059b7a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "Nemvaleukin Alfa: Accumulating Data Support Critical Design Criteria",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49f03963-7607-4ccb-a178-83f08cd40ed3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "ef967ffb-b6f8-4446-a626-cc8354a2a724",
      "evidence": "list/bullet: Clinical Benefit: Anti-tumor activity observed both as a single agent and with checkpoint inhibitors (CPI); Anti-tumor activity observed in CPI-unapproved tumor types and post-CPI settings",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 34,
      "from": 23,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "4e1affb3-fc2c-436d-a5c0-492bd8d09819",
      "evidence": "The deck presents an overview of the innovation pipeline and its potential benefits",
      "position": 0,
      "objective": "Highlighting the importance of Alkermes' innovation pipeline",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}